title: Levomepromazine (methotrimeprazine) and the last 48 hours.
abstract: Levomepromazine (previously known as methotrimeprazine) has a broad range of beneficial effects in the terminal phase of many illnesses, resulting from its combined antipsychotic, anxiolytic and sedative actions. Levomepromazine can safely be administered in a continuous subcutaneous infusion with most other commonly used drugs in palliative care.
authors.affiliation: Department of Adult and Elderly Medicine, Countess of Chester Hospital.
authors.forename: J
authors.initials: J
authors.lastname: O'Neill
authors.forename: A
authors.initials: A
authors.lastname: Fountain
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008728:Methotrimeprazine / Q000494:pharmacology / Q000627:therapeutic use*; D011595:Psychomotor Agitation / Q000628:therapy; D011618:Psychotic Disorders / Q000188:drug therapy; D013727:Terminal Care; D019452:Terminally Ill / Q000523:psychology
chemical_list: D014150:Antipsychotic Agents; D008728:Methotrimeprazine